SYS-CON MEDIA Authors: Gilad Parann-Nissany, Michael Bushong, Eric Brown, Kevin Benedict

News Feed Item

Cytovance Biologics, Inc. and Selexys Pharmaceuticals, Corp. Announce Development and cGMP Manufacturing Agreement for SELK2 Drug Product

OKLAHOMA CITY, OK -- (Marketwired) -- 05/06/14 -- Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces a development and manufacturing agreement with Selexys Pharmaceuticals, Corp., an Oklahoma City-based clinical stage biopharmaceutical company.

Selexys Pharmaceuticals is developing drugs that target certain underlying mechanisms of inflammatory diseases and cancer. SELK2 is an investigational humanized monoclonal antibody directed toward the treatment of Crohn's Disease and Multiple Myeloma. Selexys has contracted Cytovance Biologics as its CMO to provide process development, scale up and cGMP manufacturing services of SELK2 in support of a Phase I human clinical trial.

"With this agreement, Selexys continues its longstanding relationship with Cytovance," said Dr. Scott Rollins, President and CEO of Selexys. "Cytovance has been an integral part in helping us advance our clinical trial programs. We look forward to working with the company's team of professionals on this new product for the treatment of inflammatory diseases and cancer."

"Cytovance has been a manufacturing provider for Selexys since 2010 and welcomes this new project of SELK2 drug product for Phase 1 clinical materials," said Darren Head, President and Chief Executive Officer of Cytovance Biologics, Inc. "We are proud to be an established partner with Selexys and support them in finding an effective therapy for Crohn's Disease that affects nearly 500,000 patients in the U.S."

About Selexys Pharmaceuticals, Corp.

Selexys Pharmaceuticals, Corp., is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and cancer metastasis across a broad range of severe diseases. Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK. For additional information about Selexys Pharmaceuticals, visit www.selexys.com.

About Cytovance Biologics, Inc.

Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities. Learn more about Cytovance Biologics at www.cytovance.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contact
Cytovance Biologics, Inc.
Jodie Gutkowski
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.